Direct renin inhibitor adjunct not helpful in T2DM patients at high risk for CV, renal events


The direct renin inhibitor aliskiren, added to standard therapy with renin-angiotensin system blockade, in patients with type 2 diabetes who are at risk for cardiovascular and renal adverse events was not useful at lowering these events and may even be harmful, according to an online study published in the New England Journal of Medicine.

Recent Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.